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Abstract Maternalmainstream tobaccosmoking is knownto
haveadverse outcomesonfetalrespiratoryfunction; however,
no data is currently available on the effects of passive
exposure to tobacco smoking and environmental tobacco
smoke (ETS) on fetal systemic arterial structure and function.
Eight pregnant rhesus macaque monkeys were studied at the
California Regional Primate Research Center breeding colo-
ny. The estimated gestational age for each dam was
established by sonography performed before gestational
day 40. Two inhalation chambers were used, each with an
air capacity of 3.5 m
3, and each housed two dams. Aged and
diluted sidestream smoke was used as a surrogate for ETS.
Exposure to ETS (1 mg/m
3) occurred for 6 h/day, 5 days/
week, beginning on gestational day 100. All dams were
allowed to give birth spontaneously and then ETS exposure
continued 70–80 days postnatally with the chamber contain-
ing both the mother and infant. Carotid arteries from four
control (C) and four ETS-treated newborns were analyzed
for mRNA by gene macroarray and for protein by Western
blotting. A total of 588 cardiovascular genes were studied.
Four genes were upregulated by ETS compared to C, and
nine genes were downregulated (≥2-fold change). Three
genes were selected for further study. Following ETS
exposure, neonatal carotid arteries of non-human primates
manifested evidence of inflammation with increased gene
and protein expression of LFA-1 and RANTES, proteins that
are recognized to be important in vascular adhesion and
inflammation, and downregulation of expression for the
receptor for VEGF, which has a key role in angiogenesis.
Prenatal and postnatal exposure to ETS increases expression
of pro-inflammatory genes and may be responsible for early
arterial vascular remodeling that is predisposing to a
subsequent vascular disease.
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Introduction
Tobacco smoking is a major cause of morbidity and
mortality in the U.S. and an increasingly important cause
of death and disability worldwide. Further, maternal
mainstream tobacco smoking is known to have multiple
adverse fetal outcomes, including reduced fetal respiratory
function [1–12]. Exposure to tobacco smoking, either
mainstream or environmental tobacco smoke (ETS), is a
major modifiable cardiovascular risk factor known to exert
deleterious effects on fetal systemic arterial structure and
function [4, 13, 14]. This is an important area of research
because arterial disease, specifically atherosclerotic cardio-
vascular disease, is the leading cause of morbidity and
mortality in adults, which develops over decades with its
onset early in life. Multiple reports have now documented
that early and intermediate stage atheroma occurs in
children and teenagers [14–19]. Thus, it is plausible that
early injury to fetal arteries in the in utero environment can
predispose to arterial disease in adulthood.
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appreciated to have major adverse health effects and to
result in a pro-inflammatory state [20, 21]. Our previous
work showed that ETS increases endothelial layer perme-
ability, low-density lipoprotein accumulation, and stiffening
in the artery wall [21, 22]. Thus, work from a number of
laboratories, including our own, indicate that exposure to
either mainstream tobacco smoke or ETS acutely injures the
artery wall and predisposes to chronic inflammation;
however, no studies have yet been conducted that examine
the effects of ETS exposure of the mother and neonate on
the inflammatory status of the vasculature of the neonate.
Atherosclerosis has its origins in the arterial subendo-
thelium and is an inflammatory state characterized by
arterial injury [23, 24]. The vascular pathology is charac-
terized by inflammation involving a number of cells,
including blood-borne monocytes [25]. Monocyte recruit-
ment is promoted by a several factors, including cellular
adhesion molecules, such as vascular cell adhesion
molecule-1 resulting in monocyte transmigration to the
subendothelial space. In the subendothelial space, “foam
cells” or lipid-filled macrophages are formed [26]. The
interaction of macrophages and lipids play a central role in
the development of atherosclerosis through foam cell
formation and via the induction of numerous cytokines,
chemokines, such as RANTES [27], and growth factors,
including vascular endothelial growth factor (VEGF) [28].
In this study, we hypothesized that chronic maternal, fetal,
and neonatal exposure to ETS increases molecular markers
and mediators of arterial injury and inflammation in fetal
arteries.
Materials and Methods
Animals and Smoke Exposure Protocols All studies were
carried out in accordance with the declaration of Helsinki
and with the Guide for the Care and Use of Laboratory
Animals as adopted and promulgated by the National
Institutes of Health (http://oacu.od.nih.gov/regs/guide/
guide.pdf). Eight pregnant Rhesus macaque monkeys were
obtained from the California National Primate Research
Center breeding colony. Estimated gestational age for each
dam was established by sonography performed before
gestational day 40. Animals were selected based on a
history of successful vaginal delivery and previous infant
rearing experience with estimated delivery dates separated
by approximately 1 week per animal to facilitate experi-
mental procedures.
Two inhalation chambers were used, each with an air
capacity of 3.5 m
3, and each housed two dams. Aged and
diluted sidestream smoke was used as a surrogate control for
ETS. Standardized 1R4F research cigarettes were smoked
simultaneously with a single puff volume of 35 ml per
cigarette and a duration of 2 s, once per min. ETS was
generated by a smoke exposure system (Teague Enterprises,
Davis, CA) using IR4F conditioned cigarettes from the
Tobacco and Health Research Institute of the University of
Kentucky. Sidestream smoke from the smoldering end of
each cigarette was collected into a conditioning chamber
where it was aged over a period of approximately 2 to 3 min
while being diluted with filtered air and then further diluted
as it passed into the exposure chambers to produce total
suspended particulate concentrations of 1.0 mg/m
3,4 –5p p m
carbon monoxide and 200–300 μg/m
3 nicotine. This level of
exposure is highly reminiscent of ETS concentrations found
in homes or the workplace where smoking is permitted. The
exposure chambers were stainless steel and glass Hinners
type and 4.2 m
3 in size. Each chamber has an air capacity of
3.5 m
3. Airflow through the system was set for 15 changes
per hour.
Exposure to ETS (1 mg/m
3) occurred for 6 h/day, 5 days/
week, beginning on gestational day 100. All dams were
allowed to give birth spontaneously (five male and three
female infants born), and then ETS or sidestream control
exposure continued for 70–80 days postnatally for the four
experimental and four control animals, respectively with the
chamber containing both the mother and infant. Infants
were then sacrificed (mean age, 72 days) and bilateral
carotid arteries dissected and cleansed of adventitial fat.
Carotid arteries from four control and four ETS-treated
newborns (mean weight of animals at sacrifice, 0.84 kg)
were then analyzed for mRNA by gene macroarray and for
protein by Western blotting. Tissues were flash-frozen and
stored at −80°C until assayed.
RNA Isolation AllprocedureswereperformedunderRNAse-
free conditions. RNA was isolated from the carotid artery
samples from the neonatal monkeys using Tri Reagent
(Molecular Research Center, Inc., Cincinnati, OH) following
tissue disruption with a mortar and pestle and subsequent use
of a tissue hand-held glass homogenizer (Kontes). Total RNA
was extracted using chloroform or 1-Bromo-3-Chloropropane
(BCP) Phase Separation Reagent (Molecular Research). Each
carotid (25–33 mg tissue) yielded approximately 2.0–3.3 mg
of total RNA. Following extraction, RNA was treated with
DNAse using Clontech DNAse-1 per the manufacturer’s
instructions (MessageClean DNAse-1; GenHunter Corpora-
tion, Nashville, TN). Total RNA from the control and ETS-
exposed aortas were used to prepare two radioactive probes
for array hybridization.
Probe Preparation and Array Hybridization The Atlas
Human Cardiovascular cDNA Expression Array Kit and
reagents (Clontech, Palo Alto, CA) were used for these
studies. The array contains duplicate copies of 588
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ing genes (http://www.clontech.com). The cardiovascular
genes consist of six major categories as follows: (1) cell
cycle regulators/intermediate filament markers, (2) apopto-
sis/oncogenes/tumor suppressors, (3) DNA damage/repair
and cell development, (4) cell adhesion/mobility and
angiogenesis, (5) cell–cell interactions, and (6) growth
factors/cytokines.
The
33P-labeled cDNA probes were synthesized by
reverse transcription of total RNA from filtered air (control)
and environmental tobacco smoke-exposed monkey caro-
tids using a gene-specific primer mix (1μl, 0.2 μM of each
primer) and annealed to 2.13 μg of total RNA. The mixture
was heated for 2 min at 70°C in a thermal cycler (Perkin
Elmer, Waltham, MA), then incubated for 2 min at 50°C.
First strand cDNA synthesis was initiated by mixing the
annealed primer with the RNA and master mix [containing
4 μl of 5X reaction buffer (250 mM Tris–HCl, pH 8.3,
375 mM KCl, 15 mM MgCl2), 2 μl of dNTP mix (0.5 mM
of each dGTP, dCTP, and dTTP), 5 μlo f[ α-
33P]dATP
(3,000 Ci/mmol), (10 mCi/ml; NEN, Boston, MA.), 1 μl
DTT (100 mM), and 2 μl of MMLV reverse transcriptase
(50 U/μl)]. The reaction was incubated in a thermal cycler
(Perkin Elmer) at 50°C for 25 min and stopped by addition
of 1 μl termination mix [0.1 M EDTA (pH 8.0), 1 mg/ml
glycogen]. The labeled cDNA probe was purified from
unincorporated
33P-labeled nucleotides by gel filtration
chromatography using a 1-ml NucleoSpin extraction spin
column (Clontech) per the manufacturer’s instructions. The
purified-labeled cDNA probes (approximately 1X10
6 cpm
for control and ETS-exposed monkey carotid) were utilized
for macroarray hybridization.
Macroarray Hybridization The probes were prepared for
hybridization by adding 10X denaturing solution (1 M
NaOH, 10 mM EDTA) to the entire pool of labeled probe
and incubated at 68°C for 20 min. Cot-1 DNA and 2X
neutralizing solution (1 M NaH2PO4, pH 7.0) was added to
the denatured probe and incubated at 68°C for 10 min. The
labeled probe solution was mixed together with preheated
ExpressHyb hybridization solution. Each of the two
duplicate Atlas Human Cardiovascular Array membranes
were pre-wet with de-ionized H2O and prehybridized for
30 min at 68°C. Under continuous agitation, the array
membranes were hybridized overnight at 68°C, washed
three times with 2X SSC, 1% sodium dodecyl sulfate (SDS)
at 68°C, washed twice with 0.1X SSC, 0.5% SDS for
30 min at 68°C, and then washed for 5 min with 2X SSC at
room temperature (RT).
Signal Detection and Image Analysis The washed mem-
branes were sealed in plastic wrap and exposed directly to a
storage phosphor screen (Molecular Dynamics, Sunnyvale,
CA) for 8 days. The screen was scanned using Storm 840 in
storage phosphor mode. Signal intensity was quantified
using an ImageQuant software for identification of differ-
entially expressed genes. In ImageQuant, grid objects were
created and used for simultaneous quantitation of all
duplicate spots on each array. Grids of seven columns by
14 rows were used to analyze the six main gene groupings
on the macroarrays. Separate grids were created for
housekeeping gene spots and for determining background
(unspotted, unhybridized areas of the membrane), which
was subtracted from volume densitometry values for the
grid cells. Twenty-three kilo Daltons highly basic protein
and 60S ribosomal protein L13A (aka RPL 13A) house-
keeping gene values were used for normalization based on
the equality of signal strength between both arrays. This
normalization scheme was further validated by the equality
in normalized expression of many of the common genes on
both arrays.
Real-Time RT-PCR-Based Confirmation of Differential
Gene Expression To further confirm differential mRNA
expression of the genes identified to be regulated by ETS in
the macroarray analysis, we performed real-time polymer-
ase chain reaction (PCR) utilizing two additional ETS-
exposed and control monkey aortas. Thus, for these
experiments, a total of six aortas were studied for ETS-
exposed and control neonatal monkeys, respectively. The
aortas were from the same experimental animal cohort as
described earlier in the “Materials and Methods” section.
Briefly, total RNA from the ETS and control aortas was
treated with DNAse (MessageClean DNAse-I; GenHunter)
and cDNA generated by reverse transcriptase (RT)-PCR. A
mixture of oligo (dT) oligodeoxynucleotide primers (T12–
18) and random hexamer primers were used for these
studies following the protocol for SuperScript RNAse H-
Reverse Transcriptase (GibcoBRL, Rockville, MD). Real-
time detection of PCR was performed using the GeneAmp
5700 Sequence Detection System (Applied Biosystems,
Foster City, CA) according to the manufacturer’s instruc-
tions. The same gene-specific primers used for semiquan-
titative PCR analysis were used for real-time PCR detection
of the genes of interest. Equal amounts of duplicate or
triplicate sample cDNA were amplified with the SYBR
Green I Master Mix (Applied Biosystems). The thermal
cycling parameters were thermal activation for 10 min at
95°C followed by 40 cycles of PCR (melting for 15 s at 95°
C and annealing extension for 1 min at 60°C). A standard
curve was constructed using a template dilution series
(1:10, 1:20, 1:40, 1:80, and 1:160) of total RNA from
monkey aorta. A “no template” negative control was
included with each PCR. Amplification efficiency for each
of the genes of interest was then validated and normalized
against glyceraldehyde-3-phosphate dehydrogenase
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the various genes, data was expressed as the normalized
densitometry ratio of ETS to control aortas.
Western Blotting Protein was prepared from monkey carotid
sections from filtered air (control) and ETS-exposed monkeys
using Tri Reagent (Molecular Research Center, Inc., Cincin-
nati, OH) or NE-PER Nuclear and Cytoplasmic Extraction
Reagents (Pierce, Rockford, IL), and mammalian Protease
Inhibitor Cocktail (Sigma, Saint Louis, MO) per the manu-
facturer’sprotocol.Proteinquantitywasassayedbydetergent-
compatible DC protein assay (BioRad, Hercules, CA). Ready
gels for SDS-PAGE electrophoresis (BioRad) were used with
the appropriate gel concentration for the size of the protein of
interest (loading ~44 mg of protein per lane). Kaleidoscope
molecularweightmarkers(BioRad)wereloadedinoneortwo
lanes of the gels for size markers. The gels were electro-
phoresed at 60 V for 15–30 min, followed by 60–90 min at
120 V depending on the speed of migration. After electro-
phoresis, electroblotting proceeded for 1 h at 100 Von ice.
The blot was blocked in 10% w/v non-fat dry milk Tris-
Buffered Saline Tween-20 (TBST) solution overnight at 4°C.
The nitrocellulose membrane was washed three times with
TBS, 0.05% Tween. The primary antibody was diluted in
TBST to concentrations previously determined or according
to manufacturer’s recommendations and incubated for ~1 h at
RT. The secondary antibody was diluted in TBST and
incubated for ~1 h at RT. The nitrocellulose was washed
two times with TBST. Electrochemiluminescence (ECL)
Detection Reagents (Amersham Pharmacia Biotech, Buck-
inghamshire, England) horseradish peroxidase (HRP)-based
detection was used. Blots were wrapped in saran and exposed
to autoradiograph film (Kodak Biomax, Rochester, NY).
Densitometry was performed on a Kodak 1D gel imaging
system. Some blots were stripped with Restore Western Blot
Stripping Buffer (Pierce) and re-probed with mouse anti-actin
or a different primary antibody than that stripped, followed
by a secondary antibody and ECL detection as described.
Details of the antibodies used and protein products of the
genes studied (see “Results”) are as follows:RANTES (8 kDa
protein)—primary antibody goat polyclonal anti-RANTES
(Santa Cruz Biotech, Santa Cruz, CA; 1:1000 dilution) and
secondary antibody bovine anti-goat IgG HRP (Santa Cruz
Biotech; 1:10,000–1:30,000 dilution); VEGFR2 [flk-1]
(130 kDa protein)—primary antibody rabbit polyclonal anti-
neuropilin-1 (Oncogene Research Products, La Jolla, CA;
1:100–1:200 dilution) and secondary antibody goat anti-
rabbit IgG HRP (BioRad; 1:15,000 dilution), as well as
primary antibody goat polyclonal anti-neuropilin-2 (Santa
Cruz Biotech; 1:100 dilution) and secondary antibody bovine
anti-goat Ig G HRP (Santa Cruz Biotech; 1:10,000–1:30,000
dilution); LFA-1 [integrin alpha L] (180 kDa protein)—
primary antibody goal polyclonal anti-LFA1 (Santa Cruz
Biotech; 1:100 dilution) and secondary antibody bovine anti-
goat IgG HRP (Santa Cruz Biotech; 1:10,000–1:30,000
dilution); actin control (41 kDa protein)—primary antibody
mouse monoclonal anti-actin (Sigma; 1:1,000 dilution) and
secondary antibody goat anti-mouse IgG HRP (BioRad;
1:15,000 dilution).
Data Analysis Densitometry values were obtained for each
array cDNA from ETS-treated and control samples, and
quantification of spots on arrays from ETS-treated and control
(sidestream air) aortas was performed. In order to allow the
array products to be quantified comparatively, arrays were also
spotted with two housekeeping genes. This permitted the spot
densitometry values of the ETS-treated and control array
signals to be normalized to the housekeeping signals and to
calculate normalized densitometry ratios. Background signal
wassubtractedfromthecontrolandETSspotspriortoanalysis.
Normalized ratio data from the arrays were then evaluated for
differential expression (i.e., greater or less than a 2-fold
difference in expression in the ETS-treated versus the control
samples). All arrays were spotted in duplicate. Four aortas each
were used for the ETS-treated and the control arrays.
Quantification of PCR products was performed in a similar
fashion. PCR amplifications were conducted with GAPDH in
order to permit normalization of signals to GAPDH and to
account for any minor variations in DNA loading in the PCR
product signals. Normalized ratio data from PCR reactions
were then evaluated for differential expression (i.e., greater or
less than a 2-fold difference in expression in the ETS-treated
versus the control samples). All PCR reactions were
performed in duplicate. Six aortas each were used for the
ETS-treated and the control PCRs. Normalized data from
arrays and PCR were expressed as relative fold change in
expression for ETS compared to control-treated aortas.
Western blot experiments were performed in triplicate or
greater, and data expressed as mean +/− standard error of
the mean (SEM) for net densitometry values for the four
control and the four ETS-treated aortas. Means +/− SEM
and mean fold change in protein expression in the ETS-
treated and control protein products was then calculated.
Statistical significance was at the p<0.05 level.
For the array, PCR, and Western assays, the calculated
fold-change differences between the ETS-treated and
control samples were based on the mean values of the four
subjects in each of the control and study groups.
Results
Up- and Downregulated Aortic Genes by Macroarray
Analysis Macroarray analysis was performed on the neonatal
carotid arteries from animals whose mothers were exposed to
ETS or filtered air (control). Five hundred eighty-eight array
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were spotted in duplicate. A complete set of the macroarray
data for the 588 genes analyzed was submitted to the Center
for Information Biology Gene Expression Database (CIBEX
Accession: CBX26). Compared to the control, ETS upregu-
lated genes for RANTES and LFA-1 corresponded to cell
coordinate (block, row, column) Ah3 and Cn4, respectively.
ETS downregulation of VEGFR2 corresponded to cell
coordinate Aa7. Genes of interest were identified by a greater
than 2-fold increase or decrease in expression relative to the
meanhousekeepinggeneexpressionlevel.Thisresultedinthe
identification of four genes upregulated by ETS compared to
the control and nine genes downregulated by ETS compared
to the control. A summary of the differential gene expression
by ETS utilizing the Atlas human cardiovascular cDNA
expression array and their functional categorization is sum-
marized in Table 1.
Three genes of interest were identified for further study
based on the level of expression and/or their physiological/
functional significance in the vasculature as follows: (1) T
cell-specific rantes protein (RANTES) precursor, (2) leu-
kocyte adhesion glycoprotein (LFA-1; CD11a/CD18) alpha
subunit, and (3) vascular endothelial cell growth factor
receptor (VEGFR2; FLk1). RANTES and LFA-1 were
upregulated by ETS relative to filtered air control with
expression levels that were 19.7 and 8.5 greater than the
control, respectively. VEGFR2 was downregulated (2.8-
fold less) by ETS exposure relative to the control (Table 1).
Table 1 Summary of differential gene expression by ETS utilizing the atlas human cardiovascular cDNA expression array
Array coordinate
(block, row, column)
Gene name (Gene Functional Classification Category) Fold-change
expression
a
Upregulated
genes
Ah3 T cell-specific rantes protein precursor; sis delta; small inducible cytokine A5
(growth factor, cytokine and chemokines)
19.7
Bg2 Adipocyte fatty acid-binding protein 4 (trafficking and targeting proteins) 2.8
Bj6 Lumican precursor (extracellular matrix proteins) 5
Cn4 Leukocyte adhesion glycoprotein LFA-1 alpha subunit precursor; leukocyte
function-associated molecule 1 alpha chain; CD11A antigen; integrin alpha L
(cell–cell adhesion receptors)
8.5
Downregulated
genes
Aa7 Vascular endothelial cell growth factor 165 receptor [VEGF-R2] (growth factor
and chemokine receptors)
−2.8
Bk5 Caveolin 3 (GTP/GDP Exchangers and GTPase activity modulators) −2
Cg2 GAP junction alpha-1 protein (cell–cell adhesion receptors and other membrane
channels and transporters)
−2
Cl3 Integrin alpha 8 (cell–cell adhesion receptors) −2.2
Cm5 Procollagen 1 alpha 2 subunit precursor (extracellular matrix proteins) −2.9
Dj1 Profilin 1 (cytoskeleton and motility proteins) −3
Dm3 Tissue inhibitor of metalloproteinase 1 precursor [TIMP-1] (extracellular matrix
proteins and protease inhibitors)
−2.8
Ff1 N-acetylglucosamine-6-sulfatase precursor; glucosamine-6-sulfatase (complex
carbohydrate metabolism)
−4.1
Fg5 Natriuretic peptide precursor B (hormones) −4.2
aUpregulated and downregulated refer to fold change in expression level for ETS vs control. Italics denote genes selected for further study based on their
expression level and/or vascular relevance. See text for details
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Fig. 1 Western blot analysis for differentially expressed genes in
monkey carotids in response to environmental tobacco smoke (ETS)
compared to control (C). The blots demonstrate upregulation of
protein expression for RANTES and LFA-1 by ETS compared to
control (C)
700 J. of Cardiovasc. Trans. Res. (2010) 3:696–703Differential Expression of Genes of Interest We performed
RT-PCR to confirm differential expression for the genes of
interest. The expression ratios for ETS were 12.2-fold
greater than the control for LFA-1 and 1.7-fold less than the
control for VEGFR2. Despite repeated attempts, however,
we were unable to verify the differential expression for
RANTES by real-time PCR despite there being a clear
increase in gene expression for this gene by macroarray and
in protein expression by Western blotting following ETS
exposure (see below).
Next, confirmation of functional expression of the three
genes was sought by determining protein expression using
Western blotting (Fig. 1). In these studies, protein expres-
sion for RANTES and LFA-1 was increased for ETS
compared to control arteries by 6.2- and 1.7-fold, respec-
tively. These findings were in concert with the previously
observed upregulation in gene expression noted by macro-
array analysis for these genes following ETS exposure. In
contrast, protein expression for VEGFR2 was decreased
0.7-fold by ETS exposure compared to filtered air expo-
sure, in concert with downregulation in gene expression for
this gene by both macroarray and real-time PCR. A
summary of gene and protein expression level changes for
the three genes of interest is provided in Table 2.
Discussion
This study shows that inhalation of ETS by the mother
alters neonatal gene and protein expression in systemic
arteries. How ETS has these effects on fetal arteries is not
clear. The injury to fetal arteries could occur in a number of
ways, including reduced placental blood flow, activation of
platelets and leukocytes, and vascular wall inflammation.
T w og e n e sw e r eu p r e g u l a t e db yE T Sa n da r eo f
particular interest in this study: (1) RANTES (regulated
on activation of normal T cell expressed and secreted) and
(2) LFA-1 (a β2 integrin leukocyte function antigen, also
known as CD11a/CD18). These genes are pro-
inflammatory. RANTES is a small inducible cytokine that
functions as a chemoattractant and an activating cytokine
for monocyte cell recruitment to atherosclerotic plaque
[27], a chemokine for inflammatory cells [22] and mediator
of inflammation [29–31]. It is also implicated in athero-
sclerotic lesion formation as it is a macrophage inflamma-
tory protein [30] and is secreted by vascular endothelial
cells [32]. RANTES is strongly induced in response to
cellular insult. LFA-1 is a surface glycoprotein and cell
adhesion molecule that plays a key role in cell trafficking
and cell-to-cell contact, including leukocyte/monocyte
adhesion to the endothelium, one of the early events in
atherogenesis and has a role in vascular injury, as reviewed
by Galkina and Ley [33]. LFA-1 also has an important role
in the pathophysiology of inflammation and immunity [34,
35]. Thus, the coordinated upregulation by ETS of
expression for plasma membrane glycoproteins involved
in leukocyte adhesion, such as LFA-1, and chemoattrac-
tants, such as RANTES, provide a molecular mechanism
for ETS-mediated vascular injury in neonatal arteries.
These experiments also demonstrated a downregulation
of gene expression for vascular endothelial growth factor
receptor (VEGFR) by ETS exposure. VEGF is derived
from vascular smooth muscle cells and fibroblasts, acts on
endothelium, and is a key regulator of physiological and
pathological angiogenesis (tumor angiogenesis). VEGF is
found in human coronary vessels where it participates in
atherosclerosis and plaque growth and angiogenesis [36,
37]. VEGF also participates in revascularization in response
to injury and is mitogenic for vascular endothelial cells [38,
39]. Two VEGFR genes are known, the VEGFR-1 (flt-1)
and VEGFR-2 (KDR/flk-1), which are genes that encode
VEGF-specific tyrosine kinase. In this study, downregula-
tion of VEGFR2 gene expression by ETS was not
accompanied by substantial downregulation of protein
expression (~ 7% downregulation), suggesting gene regu-
lation by ETS at the translational level. Translation is the
target of multiple regulatory proteins. Translational repres-
sion of mRNA is consistent with reduced or absent
translation known as translational silencing. There are
examples of translational silencing of a complex of
inflammatory RNAs that share similar co-regulatory fac-
tors. One example is the interferon-gamma-activated trans-
lational inhibitor (GATI) complex known to be involved in
translational silencing. Inflammatory genes are known to be
a target of this pathway. Although no prior negative
translational regulation had been previously described for
VEGF, this gene has recently been reported to be a target of
the GATI pathway [40]. Since the endothelial cell-specific
VEGF and its cellular receptors Flt-1 and Flk-1 have been
implicated in the formation of the embryonic vasculature,
this mechanism of translational silencing by ETS of an
angiogenesis gene may be of potential importance in local
angiogenic responses and in regulating translational inhibi-
tion of angionesis.
Table 2 Comparison of gene macrochip array, real-time PCR, and
Westernblotproteinexpressionforthethreegenesofinterestinthisstudy
Fold change in expression for ETS vs filtered air control
Gene array Real-time PCR Protein
RANTES +19.7 n/a +6.2
LFA-1 (CD11a/CD18) +8.5 +12.2 +1.7
VEGFR-2 (Flk-1) −2.8 −1.7 −0.7
ETS environmental tobacco smoke, C control (filtered air)
J. of Cardiovasc. Trans. Res. (2010) 3:696–703 701This study has limitations. A major question posed is
whether arterial injury that occurs in the pre- and
postnatal period has long-term adverse outcomes. There
is some precedence for this in asthma where rodent
studies have shown that perinatal exposure to tobacco
smoke early in life increased airway responsiveness later
[6]; however, our studies were not designed to address
these long-term questions. An additional limitation relates
to the lack of success in amplifying the RANTES gene for
real-time PCR confirmation of the macroarray findings.
Further attempts were limited by lack of availability of
additional tissue; however, we are confident of our
findings given concomitant upregulation of gene expres-
sion by macroarray and protein expression by Western
blotting for this gene. Atherosclerosis lesion development
was not directly studied because the animals were not
hyperlipidemic or cholesterol-fed, and they were of a very
young age (70–80 days). In addition, biomarkers of
exposure were not analyzed because the primary focus of
the study was the molecular changes in the carotid
arteries; however, a recent publication by a co-author of
the present study [41] utilized a similar system to
demonstrate biomarkers of ETS exposure are present;
following 1 year of postnatal exposure, non-human
primates’ aortas were found to have increased vascular
oxidative stress (protein carbonyls and SOD) and mito-
chondrial dysfunction/damage (cytochrome oxidase, mi-
tochondrial DNA) that were coupled to reductions in
mitochondrial antioxidant capacity and copy number in
vascular tissue compared to filtered air-exposed controls.
Furthermore, basic histologic analysis suggested early
atherosclerotic changes in smoke exposed aortas. These
findings may be of significance in explaining the potential
for increased atherosclerotic disease susceptibility in
adulthood following early life smoke exposure because
inflammation and mitochondrial damage and dysfunction
in response to tobacco smoke exposure are features of
early atherosclerosis.
In conclusion, our study demonstrates that prenatal and
postnatal maternal exposure to environmental tobacco
smoke increases neonatal arterial expression of genes that
are pro-inflammatory and induce or contribute to vascular
injury while reducing the arterial expression of a gene for
angiogenesis. These observations have not been previously
reported and provide a molecular explanation for early
deleterious effects of ETS on the vasculature that relates to
at least two vascular physiologic processes: activation of a
pro-inflammatory gene cascade and inhibition of vascular
repair to injury via inhibition of angiogenic genetic control.
Further studies are needed to determine if the arterial injury
and activation observed in neonatal vessels in response to
ETS exposure will translate into increased susceptibility to
vascular disease later in life.
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